Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%

Rituximab vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.11 [0.72, 1.71]
2 studies · 241 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25
1 study · 140 participants
Low

Azathioprine vs cyclophosphamide

Serious adverse events · adults with renal vasculitis for maintenance therapy

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.18 [0.45, 3.07]
1 study · 144 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.49 [0.16, 1.56]
1 study · 131 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Adverse events: treatment failure (non response, serious infection, persistently elevated creatinine) at 6 months · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.32 [0.18, 0.58]
1 study · 124 participants
Moderate